{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-26-008771","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2026-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.275815+00:00","generated_at":"2026-05-15T04:29:47.466762+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Tonix reports preclinical data for TNX-1700 and TNX-4700 at AACR 2026","bullets":["TNX-1700 reversed aging-associated gastric inflammation and attenuated tumor progression in aged mouse model.","TNX-1700 showed dose-independent linear PK in non-human primates and transgenic mice; no significant weight loss.","TNX-4700 anti-BTLA mAbs demonstrated potent, high-affinity binding and functional antagonism in vitro.","Three TNX-4700 antagonists had reduced FcgRI binding and no FcgRIIB binding, potentially lowering FcR-dependent toxicities."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-26-008771","json":"https://secwatch.observer/filing/0001999371-26-008771.json","markdown":"https://secwatch.observer/filing/0001999371-26-008771.md","text":"https://secwatch.observer/filing/0001999371-26-008771.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126008771/0001999371-26-008771-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126008771/tnxp_8k-042226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:29:47.466762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}